Maki Kevin C, Dicklin Mary R, Baum Seth J
Metabolic Sciences, Midwest Center for Metabolic & Cardiovascular Research, 489 Taft Avenue, Suite 202, Glen Ellyn, IL 60137, USA.
Metabolic Sciences, Midwest Center for Metabolic & Cardiovascular Research, 489 Taft Avenue, Suite 202, Glen Ellyn, IL 60137, USA.
Cardiol Clin. 2015 May;33(2):233-43. doi: 10.1016/j.ccl.2015.02.004.
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes. The NLA panel advocated following the standards of care from the American Diabetes Association for screening and diagnosis of diabetes, and emphasized the importance of lifestyle modification. This article summarizes NLA's review of the evidence, expanding it to include recent results, and outlines the clinical recommendations.
他汀类药物是血脂异常的一线药物治疗。临床试验数据表明，使用他汀类药物会使新发2型糖尿病的发病率增加。美国国家脂质协会（NLA）他汀类药物与糖尿病安全特别工作组得出结论，他汀类药物治疗对心血管的益处超过了患糖尿病的风险。NLA专家组主张遵循美国糖尿病协会的糖尿病筛查和诊断护理标准，并强调生活方式改变的重要性。本文总结了NLA对证据的审查，将其扩展以纳入近期结果，并概述了临床建议。
